A Scoping Review on Patient Heterogeneity in Economic Evaluations of Precision Medicine Based on Basket Trials Publisher Pubmed



Nosrati M¹ ; Nikfar S^{1, 2} ; Hasanzad M^{2, 3} Show Affiliations
Source: Expert Review of Pharmacoeconomics and Outcomes Research Published:2022

Abstract

Introduction: Considerable challenges in the economic evaluation of precision medicines have been mentioned in previous studies. However, they have not addressed how an economic assessment would be conducted based on basket trials (novel studies for evaluation of precision medicine effects) in which the included populations have specific biomarkers and various cancers. Since basket trial populations have remarkable heterogeneity, this study aims to investigate the concept of heterogeneity and specific method(s) for considering it in economic evaluations through guidelines and studies that could be applicable in economic evaluation based on basket trials. Area covered: We searched PubMed, Web of Science, Scopus, Google Scholar, and Google to find studies and pharmacoeconomics guidelines. The inclusion criteria included subjects of patient heterogeneity and suggested explicit method(s). Thirty-nine guidelines and 43 studies were included and evaluated. None of these materials mentioned disease types in a target population as a factor causing heterogeneity. Moreover, in economic evaluations, patient heterogeneity has been considered with four general approaches subgroup analysis, individual-based models, sensitivity analysis, and regression models. Expert opinion: Type of disease is not considered a contributing factor in population heterogeneity, and the probable appropriate method for this issue could be individual-based models. © 2022 Informa UK Limited, trading as Taylor & Francis Group.